Rotarix is an oral vaccine designed to protect infants and young children against rotavirus infections, which are a leading cause of severe diarrhea and dehydration in young children worldwide. The vaccine is derived from a live attenuated strain of the rotavirus, specifically tailored to combat the virus strains most commonly responsible for infections in humans. Administered orally in a two-dose schedule, Rotarix stimulates the body's immune system to build protection against the virus, significantly reducing the risk of developing severe rotavirus gastroenteritis. The World Health Organization (WHO) recommends the inclusion of rotavirus vaccines, such as Rotarix, in national immunization programs globally, especially in areas with high incidence of rotavirus-associated deaths. Rotarix is generally well-tolerated, with a safety profile that supports its use in infants as young as six weeks of age.